Concurrently, BTK inhibition impairs G-CSF receptor signaling (reduced STAT5 phosphorylation) while enhancing CXCR4-mediated marrow retention, explaining why plerixafor outperforms G-CSF monotherapy in mitigating neutropenia [34]. This evidence concerns the gene CSF3R and neutropenia.